09:17:40 EST Wed 12 Dec 2018
Enter Symbol
or Name

Login ID:
Biocube Inc
Symbol U : BICB
Recent Sedar Documents

Biocube defendant Argyros pleads guilty

2017-11-10 10:34 ET - Street Wire

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Mike Caswell

Dimitrios Argyros, one of those charged for planning the $2-million pump-and-dump of a purported marijuana breathalyzer company, has pleaded guilty. (All figures are in U.S. dollars.) Mr. Argyros entered the plea before New York judge Roslynn Masukopf on Wednesday, Nov. 8. He remains free on a $750,000 appearance bond.

Prosecutors claim that Mr. Argyros was part of a scheme to boost Biocube Inc., an OTC Markets listing, with the help of a group of as-yet-unidentified Canadians. The men planned to manipulate the stock as high as $1 and sell shares through offshore accounts, according to the government. The Canadian group would have received 30 per cent of the profits. Mr. Argyros, who was also known as "Jimmy," was to set up bank and brokerage accounts in Cyprus as part of the scheme.

The terms of Mr. Argyros's guilty plea have not been released. He is, however, the only defendant to plead guilty in the case (at least so far), which means that he may have had information to offer prosecutors about his co-defendants or others. Those co-defendants include his cousin, Chris Messalas, who the government accuses of masterminding the pump-and-dump. Mr. Messalas previously pleaded not guilty and is free on a $1-million appearance bond. (Family gatherings are undoubtedly more than a little awkward, as the terms of release for both men bar them from associating with their co-defendants.)

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2018 Canjex Publishing Ltd. All rights reserved.

Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.

Comments for this item are closed